Endobarrier, a reversible device to cure type-2 diabetes and obesity is absolutely safe to use
People suffering from type-2 diabetes and obesity now seek a non-surgical and reversible device for a cure. Researchers revealed that this obesity and diabetes combating devices are safe and effective to use and hence should be rolled out across the National Health Service (NHS). The device which goes by the name Endobarrier is a reversible treatment for people with an alternative to drastic gastric bypass surgery. It prevents food from coming into contact with the first part of the small intestine, but without needing the painful invasive surgery.
Endobarrier consists of a 60-cm long tube-like liner or sleeve that covers the inside of the small intestine, allowing the food to pass through but not to be absorbed. It can be removed after a year. This procedure intends to kick start a change in lifestyle and help people achieve their health goals, improve diabetes as well as promote healthy weight loss.
The Endobarrier therapy could be "highly effective in patients with obesity and diabetes that has been very hard to treat, with high patient satisfaction levels, and an acceptable safety profile", said Robert Ryder and colleagues from City Hospital, Birmingham
"The Endobarrier service could be a safe and cost-effective treatment for the NHS -- it does not involve surgery and patients do not have to stay in hospital (so reducing the risk of infection)," Ryder added.
The study was presented at 2017 European Association for the Study of Diabetes (EASD) Annual Meeting in Portugal. In the study, the team investigated whether this new therapy can be transformed into major clinical success by creating a small NHS Endobarrier service for people struggling to manage their weight or type-2 diabetes.
The participants reported substantial progress in health, energy and ability to exercise with around 94% of them saying that they will recommend the service to their friends and families as well.
(With IANS Inputs)
For more Lifestyle stories, follow our Facebook page.